Abstract: Provided are a vilazodone solid dispersion, a preparation method therefor and a use thereof, wherein the vilazodone solid dispersion contains an active ingredient' vilazodone, a water-soluble polymer carrier material and a surfactant. The water-soluble polymer carrier material is selected from at least one of polyvidone, copovidone and hydroxypropyl methylcellulose. The vilazodone is present in the solid dispersion in a non-crystalline state. The solid dispersion has good stability and significantly improves the solubility and in-vitro dissolution rate of the vilazodone, thereby significantly increasing the oral bioavailability thereof. The vilazodone solid dispersion can be used for preparing vilazodone-related preparations.

Abstract: An FGF21 polypeptide has one or more of the following properties: stable structure, long half-life, low immunogenicity, high biological activity, and enhanced glucose-lowering and lipid-lowering activities. A fusion protein or immunoconjugate includes the FGF21 polypeptide.

Abstract: A dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B, specifically, is a compound having Formula (I) or (Ia), or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification; and also includes the use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

Abstract: A fused tetracyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. A compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B, wherein each variable is as defined in the specification.

Abstract: A class of fluorine-substituted indazole compounds and uses thereof having the general formula depicted below in which C1 is where is the bond through which C1 is attached to L, and C2 is where is the bond through which C2 is attached to indazole, and pharmaceutical compositions containing these compounds. The compounds and pharmaceutical compositions of the invention can be used as soluble guanylate cyclase simulators.

Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

Abstract: A pyrrolidineamide derivatives and uses thereof, specifically, the present invention relates to a novel pyrrolidineamide compound and a pharmaceutical composition containing this compound, which can be used as a MAO-B inhibitor. The present invention also relates to methods of preparing this compound and pharmaceutical composition, and their use in the manufacture of a medicament for treating a disease regulated by MAO-B comprising a neurodegenerative disease, especially Parkinson's disease.

Abstract: A salt of a substituted urea derivative of formula (I) and use thereof in the pharmaceutical field. Also, a pharmaceutical composition containing the salt or a combination thereof, and use of the salt or the pharmaceutical composition in the manufacture of a medicament for treating, remitting or preventing a disorder related to tyrosine kinase activity.

Abstract: Nitrogenous tricyclic compounds and uses thereof in medicine, in particular, a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a geometrical isomer, a tautomer, a N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and use of the compound in the manufacture of a drug for treating a disease and/or disorder regulated by FXR. A pharmaceutically acceptable composition containing the compound and a method of treating a disease and/or disorder mediated by FXR comprising administering the compound or pharmaceutical composition thereof.

Abstract: A glucopyranosyl derivative is used as an inhibitor of sodium-dependent glucose transporters (SGLTs), particularly being used as an inhibitor of sodium-dependent glucose transporter-1 (SGLT1), and a pharmaceutically acceptable salt or stereoisomer thereof, further relating to a pharmaceutical composition containing the derivative. The compound and a pharmaceutical composition is used thereof in the preparation of a drug for treating diabetes and diabetes-related diseases.

Abstract: The present invention provides salts of pyrazolo[1,5-?]pyridine derivative and use thereof. The invention also relates to a pharmaceutically acceptable composition comprising such salts and a method of using the salts and the pharmaceutically acceptable composition to prevent or treat a proliferative disorder or pulmonary fibrosis in a patient.

Abstract: A dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also, use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.

Abstract: Disclosed are a compound as shown in formula (I) as an influenza virus replication inhibitor and a preparation method therefor, a pharmaceutical composition comprising the compound and the use of the compound and pharmaceutical composition thereof in the treatment of influenza.

Abstract: Provided herein is inhibitors of influenza virus replication and uses thereof. Specifically, provided herein a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

Abstract: A lurasidone solid dispersion and a preparation method thereof. The solid dispersion includes a mixture of lurasidone, a pharmaceutical carrier and a plasticizer, in which the lurasidone is in a free base form. The lurasidone solid dispersion obtained by the preparation method has characteristics of high dissolution rate (over 30%) in partial neutral medium (such as pH 6.0), significantly increased bioavailability, and significantly reduced food effect, which overcomes the excessive medication limitation in the prior art, avoids the reduction or even inefficiency of the curative effect caused by improper medication of patients, ensures the normal exertion of the medication effect, thereby increases the flexibility and compliance of patients to take medicine.

Abstract: It relates to a lurasidone solid dispersion and a preparation method, wherein the method comprises melting treatment of a mixture containing lurasidone, a medicinal hot melt carrier, optionally an acidic regulator and plasticizer in order to obtain the solid dispersion described herein, and wherein the lurasidone is provided in a form of free base. The lurasidone solid dispersion obtained by the preparation method according to the example of the invention has the characteristics of high dissolution rate (dissolution rate can reach 30%-70%) in a partial neutral medium (e.g. pH6.0). The bioavailability of lurasidone solid dispersion increased significantly and the food effect of lurasidone solid dispersion prepared from the example decreased remarkably.

Abstract: A glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.

Abstract: A fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variable is as defined in the specification. The present invention also relates to the use of a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.

Abstract: A phenyl-substituted dihydronaphthyridine compound and use thereof, and further relates to a pharmaceutical composition including the compound. According to the present invention, the compound or the pharmaceutical composition can be used as a mineralocorticoid receptor antagonist.

Abstract: A fibroblast growth factor 21 (FGF21) variant, further to a FGF21 variant fusion protein, a protein multimer, and use thereof can significantly improve the binding ability with the target and can be used to treat metabolic diseases.